BMP signalling: Agony and antagony in the family

Trends in Cell Biology

Volumn 25, Issue 5, 2015, Pages 249-264

  Brazil, Derek P ^a   Church, Rachel H ^a   Surae, Satnam ^b   Godson, Catherine ^b   Martin, Finian ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antagonist; Bone morphogenetic proteins; Disease; Gremlin; MiRNA

Indexed keywords

BONE MORPHOGENETIC PROTEIN; MICRORNA; GREM1 PROTEIN, HUMAN; PROTEIN BINDING; SIGNAL PEPTIDE;

CRYSTAL STRUCTURE; DIABETIC RETINOPATHY; HUMAN; KIDNEY DISEASE; LIVER DISEASE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; GENE EXPRESSION REGULATION; MOUSE; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY;

MAMMALIA;

ANIMALS; BONE MORPHOGENETIC PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICRORNAS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 84928057976     PISSN: 09628924     EISSN: 18793088     Source Type: Journal    
DOI: 10.1016/j.tcb.2014.12.004     Document Type: Review

References (195)

1. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
2. Miyazaki T., et al. Oversulfated chondroitin sulfate-E binds to BMP-4 and enhances osteoblast differentiation. J. Cell. Physiol. 2008, 217:769-777.
3. Hang Q., et al. Asparagine-linked glycosylation of bone morphogenetic protein-2 is required for secretion and osteoblast differentiation. Glycobiology 2014, 24:292-304.
4. Kaplan F.S., et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 2009, 30:379-390.
5. Bagarova J., et al. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol. Cell. Biol. 2013, 33:2413-2424.
6. Lopez-Rovira T., et al. Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J. Biol. Chem. 2002, 277:3176-3185.
7. Rider C.C., Mulloy B. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem. J. 2010, 429:1-12.
8. Walsh D.W., et al. Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol. 2010, 20:244-256.
9. Cui Y., et al. BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J. 1998, 17:4735-4743.
10. Constam D.B. Regulation of TGFβ and related signals by precursor processing. Semin. Cell Dev. Biol. 2014, 32:85-97.
11. Nachtigal P., et al. The role of Endoglin in atherosclerosis. Atherosclerosis 2012, 224:4-11.
12. Alt A., et al. Structural and functional insights into Endoglin ligand recognition and binding. PLoS ONE 2012, 7:e29948.
13. Halbrooks P.J., et al. Role of RGM coreceptors in bone morphogenetic protein signaling. J. Mol. Signal. 2007, 2:4.
14. Babitt J.L., et al. Bone morphogenetic protein signaling by Hemojuvelin regulates hepcidin expression. Nat. Genet. 2006, 38:531-539.
15. Yeo C., Whitman M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol. Cell 2001, 7:949-957.
16. Shi W., et al. Endofin acts as a Smad anchor for receptor activation in BMP signaling. J. Cell Sci. 2007, 120:1216-1224.
17. Tsukazaki T., et al. SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell 1998, 95:779-791.
18. Nakano N., et al. C18 ORF1, a novel negative regulator of transforming growth factor-beta signaling. J. Biol. Chem. 2014, 289:12680-12692.
19. Sflomos G., et al. ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN. J. Cell Sci. 2011, 124:3209-3222.
20. Runyan C.E., et al. Phosphatidylinositol 3-kinase and Rab5 GTPase inversely regulate the Smad anchor for receptor activation (SARA) protein independently of transforming growth factor-β1. J. Biol. Chem. 2012, 287:35815-35824.
21. Toy W., et al. EGF-induced tyrosine phosphorylation of endofin is dependent on PI3K activity and proper localization to endosomes. Cell. Signal. 2010, 22:437-446.
22. Kostaras E., et al. SARA and RNF11 interact with each other and ESCRT-0 core proteins and regulate degradative EGFR trafficking. Oncogene 2013, 32:5220-5232.
23. Xu J., et al. Arginine methylation initiates BMP-induced Smad signaling. Mol. Cell 2013, 51:5-19.
24. Feng X.H., Derynck R. Specificity and versatility in TGF-β signaling through Smads. Annu. Rev. Cell Dev. Biol. 2005, 21:659-693.
25. Massague J., et al. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.
26. Spiekerkoetter E., et al. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J. Clin. Invest. 2013, 123:3600-3613.
27. Groppe J.C., et al. In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 2011, 194:291-295.
28. Chaikuad A., et al. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J. Biol. Chem. 2012, 287:36990-36998.
29. Vogt J., et al. Protein associated with SMAD1 (PAWS1/FAM83G) is a substrate for type I bone morphogenetic protein receptors and modulates bone morphogenetic protein signalling. Open Biol. 2014, 4:130210.
30. Wiater E., et al. Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions. J. Biol. Chem. 2006, 281:17011-17022.
31. Kirkbride K.C., et al. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J. Biol. Chem. 2008, 283:7628-7637.
32. Hill C.R., et al. BMP2 signals loss of epithelial character in epicardial cells but requires the type III TGFβ receptor to promote invasion. Cell. Signal. 2012, 24:1012-1022.
33. 1 integrin and TGF-β pathway crosstalk in endothelial cells. EMBO J. 2012, 31:3885-3900.
34. Holtzhausen A., et al. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J. 2014, 28:1248-1267.
35. Daly A.C., et al. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol. Cell. Biol. 2008, 28:6889-6902.
36. Liu I.M., et al. TGFβ-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFβ switch. EMBO J. 2009, 28:88-98.
37. Gronroos E., et al. Transforming growth factor beta inhibits bone morphogenetic protein-induced transcription through novel phosphorylated Smad1/5-Smad3 complexes. Mol. Cell. Biol. 2012, 32:2904-2916.
38. Zhang R., et al. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 2013, 52:145-156.
39. Mandal C.C., et al. Reactive oxygen species derived from Nox4 mediate BMP2 gene transcription and osteoblast differentiation. Biochem. J. 2011, 433:393-402.
40. Mamidi A., et al. Signaling crosstalk between TGFβ and Dishevelled/Par1b. Cell Death Differ. 2012, 19:1689-1697.
41. Hiepen C., et al. BMP2-induced chemotaxis requires PI3K p55γ/p110α-dependent phosphatidylinositol (3,4,5)-triphosphate production and LL5β recruitment at the cytocortex. BMC Biol. 2014, 12:43.
42. Guillot N., et al. BAMBI regulates angiogenesis and endothelial homeostasis through modulation of alternative TGFβ signaling. PLoS ONE 2012, 7:e39406.
43. Avsian-Kretchmer O., Hsueh A.J. Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists. Mol. Endocrinol. 2004, 18:1-12.
44. Groppe J., et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 2002, 420:636-642.
45. Harrington A.E., et al. Structural basis for the inhibition of activin signalling by Follistatin. EMBO J. 2006, 25:1035-1045.
46. Nolan K., et al. Structure of protein related to Dan and Cerberus: insights into the mechanism of bone morphogenetic protein antagonism. Structure 2013, 21:1417-1429.
47. Zhang J.L., et al. Crystal structure analysis reveals how the Chordin family member Crossveinless 2 blocks BMP-2 receptor binding. Dev. Cell 2008, 14:739-750.
48. Scheufler C., et al. Crystal structure of human bone morphogenetic protein-2 at 2.7Å resolution. J. Mol. Biol. 1999, 287:103-115.
49. Allendorph G.P., et al. Structure of the ternary signaling complex of a TGF-β superfamily member. Proc. Natl Acad. Sci. U.S.A. 2006, 103:7643-7648.
50. Keller S., et al. Molecular recognition of BMP-2 and BMP receptor IA. Nat. Struct. Mol. Biol. 2004, 11:481-488.
51. Nickel J., et al. Intricacies of BMP receptor assembly. Cytokine Growth Factor Rev. 2009, 20:367-377.
52. Lin S.J., et al. The structural basis of TGF-β, bone morphogenetic protein, and activin ligand binding. Reproduction 2006, 132:179-190.
53. Thompson T.B., et al. The structure of the Follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev. Cell 2005, 9:535-543.
54. Fiebig J.E., et al. The clip-segment of the von Willebrand domain 1 of the BMP modulator protein Crossveinless 2 is preformed. Molecules 2013, 18:11658-11682.
55. Troilo H., et al. Nanoscale structure of the BMP antagonist Chordin supports cooperative BMP binding. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:13063-13068.
56. Kattamuri C., et al. Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers. J. Mol. Biol. 2012, 424:313-327.
57. Stafford D.A., et al. Cooperative activity of Noggin and Gremlin 1 in axial skeleton development. Development 2011, 138:1005-1014.
58. Sheth R., et al. Decoupling the function of Hox and Shh in developing limb reveals multiple inputs of Hox genes on limb growth. Development 2013, 140:2130-2138.
59. Kelley R., et al. A concentration-dependent endocytic trap and sink mechanism converts Bmper from an activator to an inhibitor of Bmp signaling. J. Cell Biol. 2009, 184:597-609.
60. Alborzinia H., et al. Quantitative kinetics analysis of BMP2 uptake into cells and its modulation by BMP antagonists. J. Cell Sci. 2013, 126:117-127.
61. Heinke J., et al. Antagonism and synergy between extracellular BMP modulators Tsg and BMPER balance blood vessel formation. J. Cell Sci. 2013, 126:3082-3094.
62. Moreno-Miralles I., et al. Bone morphogenetic protein endothelial cell precursor-derived regulator regulates retinal angiogenesis in vivo in a mouse model of oxygen-induced retinopathy. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2216-2222.
63. Ahmed M.I., et al. MicroRNA-21 is an important downstream component of BMP signalling in epidermal keratinocytes. J. Cell Sci. 2011, 124:3399-3404.
64. Kang H., et al. Inhibition of microRNA-302 (miR-302) by bone morphogenetic protein 4 (BMP4) facilitates the BMP signaling pathway. J. Biol. Chem. 2012, 287:38656-38664.
65. Guo M., et al. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. Carcinogenesis 2014, 35:1698-1706.
66. Zumbrennen-Bullough K.B., et al. MicroRNA-130a is up-regulated in mouse liver by iron deficiency and targets the bone morphogenetic protein (BMP) receptor ALK2 to attenuate BMP signaling and hepcidin transcription. J. Biol. Chem. 2014, 289:23796-23808.
67. Long J., et al. MicroRNA-22 is a master regulator of bone morphogenetic protein-7/6 homeostasis in the kidney. J. Biol. Chem. 2013, 288:36202-36214.
68. Morrissey J., et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J. Am. Soc. Nephrol. 2002, 13(Suppl. 1):S14-S21.
69. Cao H., et al. The Pitx2:miR-200c/141:Noggin pathway regulates Bmp signaling and ameloblast differentiation. Development 2013, 140:3348-3359.
70. Ning G., et al. MicroRNA-92a upholds Bmp signaling by targeting Noggin3 during pharyngeal cartilage formation. Dev. Cell 2013, 24:283-295.
71. Graham J.R., et al. MicroRNA-27b targets Gremlin 1 to modulate fibrotic responses in pulmonary cells. J. Cell. Biochem. 2014, 115:1539-1548.
72. Khokha M.K., et al. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat. Genet. 2003, 34:303-307.
73. Michos O., et al. Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 2004, 131:3401-3410.
74. Huang H., et al. Gremlin induces cell proliferation and extracellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway. BMC Nephrol. 2013, 14:33.
75. Rodrigues-Diez R., et al. Gremlin is a downstream profibrotic mediator of transforming growth factor-beta in cultured renal cells. Nephron Exp. Nephrol. 2012, 122:62-74.
76. Li Y., et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes aristolochic acid-induced epithelial-to-mesenchymal transition (EMT) in HK-2 cells. Toxicology 2012, 297:68-75.
77. Chen B., et al. Cutting edge: bone morphogenetic protein antagonists Drm/Gremlin and Dan interact with Slits and act as negative regulators of monocyte chemotaxis. J. Immunol. 2004, 173:5914-5917.
78. Tamminen J.A., et al. Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor Slug. Oncogenesis 2013, 2:e66.
79. Mitola S., et al. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 2010, 116:3677-3680.
80. Chiodelli P., et al. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist Gremlin. Arterioscler. Thromb. Vasc. Biol. 2011, 31:e116-e127.
81. 3 integrin in Gremlin-induced angiogenesis. Angiogenesis 2013, 16:235-243.
82. Shekels L.L., et al. The effects of Gremlin1 on human umbilical cord blood hematopoietic progenitors. Blood Cells Mol. Dis. 2014, 54:103-109.
83. Simoes Sato A.Y., et al. BMP-2 and -4 produced by vascular smooth muscle cells from atherosclerotic lesions induce monocyte chemotaxis through direct BMPRII activation. Atherosclerosis 2014, 235:45-55.
84. Curran S.P., et al. Deletion of Gremlin1 increases cell proliferation and migration responses in mouse embryonic fibroblasts. Cell. Signal. 2012, 24:889-898.
85. Tanwar V., et al. Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. Stem Cells 2014, 32:1774-1788.
86. Bok J., et al. Role of hindbrain in inner ear morphogenesis: analysis of Noggin knockout mice. Dev. Biol. 2007, 311:69-78.
87. Zouvelou V., et al. Deletion of BMP7 affects the development of bones, teeth, and other ectodermal appendages of the orofacial complex. J. Exp. Zool. B Mol. Dev. Evol. 2009, 312B:361-374.
88. Zouvelou V., et al. Generation and functional characterization of mice with a conditional BMP7 allele. Int. J. Dev. Biol. 2009, 53:597-603.
89. Sneddon J.B., et al. Bone morphogenetic protein antagonist Gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl Acad. Sci. U.S.A. 2006, 103:14842-14847.
90. Karagiannis G.S., et al. Enrichment map profiling of the cancer invasion front suggests regulation of colorectal cancer progression by the bone morphogenetic protein antagonist, Gremlin-1. Mol. Oncol. 2013, 7:826-839.
91. Karagiannis G.S., et al. Bone morphogenetic protein antagonist Gremlin-1 regulates colon cancer progression. Biol. Chem. 2014, Published online August 6, 2014. 10.1515/hsz-2014-0221.
92. Chen M.H., et al. Expression of Gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. J. Gastroenterol. 2013, 48:101-108.
93. Hsu M.Y., et al. Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation. Lab. Invest. 2008, 88:842-855.
94. Gao H., et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150:764-779.
95. Owens P., et al. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene 2014, Published online July 7, 2014. 10.1038/onc.2014.189.
96. Yan K., et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 2014, 28:1085-1100.
97. Seoane J. Gremlins sabotage the mechanisms of cancer stem cell differentiation. Cancer Cell 2014, 25:716-717.
98. Hardee M.E., et al. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta. Cancer Res. 2012, 72:4119-4129.
99. Tabe Y., et al. TGF-β-neutralizing antibody 1D11 enhances cytarabine-induced apoptosis in AML cells in the bone marrow microenvironment. PLoS ONE 2013, 8:e62785.
100. Sartori R., et al. TGFβ and BMP signaling in skeletal muscle: potential significance for muscle-related disease. Trends Endocrinol. Metab. 2014, 25:464-471.
101. Kim M., et al. Gremlin-1 induces BMP-independent tumor cell proliferation, migration, and invasion. PLoS ONE 2012, 7:e35100.
102. Henley K.D., et al. Inactivation of the dual Bmp/Wnt inhibitor Sostdc1 enhances pancreatic islet function. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E752-E761.
103. Kane R., et al. Gremlin gene expression in bovine retinal pericytes exposed to elevated glucose. Br. J. Ophthalmol. 2005, 89:1638-1642.
104. Lee H., et al. The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest. Ophthalmol. Vis. Sci. 2007, 48:4291-4299.
105. Ma B., et al. TGF-β2 induces transdifferentiation and fibrosis in human lens epithelial cells via regulating gremlin and CTGF. Biochem. Biophys. Res. Commun. 2014, 447:689-695.
106. Sethi A., et al. Role of TGFβ/Smad signaling in Gremlin induction of human trabecular meshwork extracellular matrix proteins. Invest. Ophthalmol. Vis. Sci. 2011, 52:5251-5259.
107. Sethi A., et al. Gremlin utilizes canonical and non-canonical TGFβ signaling to induce lysyl oxidase (LOX) genes in human trabecular meshwork cells. Exp. Eye Res. 2013, 113:117-127.
108. McMahon R., et al. IHG-2, a mesangial cell gene induced by high glucose, is human Gremlin. Regulation by extracellular glucose concentration, cyclic mechanical strain, and transforming growth factor-β1. J. Biol. Chem. 2000, 275:9901-9904.
109. Murphy M., et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem. 1999, 274:5830-5834.
110. Dolan V., et al. Gremlin - a putative pathogenic player in progressive renal disease. Exp. Opin. Ther. Targets 2003, 7:523-526.
111. Roxburgh S.A., et al. Allelic depletion of Grem1 attenuates diabetic kidney disease. Diabetes 2009, 58:1641-1650.
112. Zhang Q., et al. In vivo delivery of Gremlin siRNA plasmid reveals therapeutic potential against diabetic nephropathy by recovering bone morphogenetic protein-7. PLoS ONE 2010, 5:e11709.
113. Droguett A., et al. Tubular overexpression of gremlin induces renal damage susceptibility in mice. PLoS ONE 2014, 9:e101879.
114. Li G., et al. Gremlin aggravates hyperglycemia-induced podocyte injury by a TGFβ/Smad dependent signaling pathway. J. Cell. Biochem. 2013, 114:2101-2113.
115. Michos O., et al. Reduction of BMP4 activity by Gremlin 1 enables ureteric bud outgrowth and GDNF/WNT11 feedback signalling during kidney branching morphogenesis. Development 2007, 134:2397-2405.
116. Goncalves A., Zeller R. Genetic analysis reveals an unexpected role of BMP7 in initiation of ureteric bud outgrowth in mouse embryos. PLoS ONE 2011, 6:e19370.
117. Dendooven A., et al. Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis. Am. J. Pathol. 2011, 178:1069-1079.
118. Jenkins R.H., Fraser D.J. BMP-6 emerges as a potential major regulator of fibrosis in the kidney. Am. J. Pathol. 2011, 178:964-965.
119. Tanaka M., et al. Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury. Kidney Int. 2008, 73:181-191.
120. Tanaka M., et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J. Clin. Invest. 2010, 120:768-777.
121. Hamasaki Y., et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway. Lab. Invest. 2012, 92:1161-1170.
122. Kiso H., et al. Interactions between BMP-7 and USAG-1 (uterine sensitization-associated gene-1) regulate supernumerary organ formations. PLoS One 2014, 9:e96938.
123. Yamada S., et al. Twisted gastrulation, a BMP antagonist, exacerbates podocyte injury. PLoS ONE 2014, 9:e89135.
124. Boers W., et al. Transcriptional profiling reveals novel markers of liver fibrogenesis: Gremlin and insulin-like growth factor-binding proteins. J. Biol. Chem. 2006, 281:16289-16295.
125. Guimei M., et al. Gremlin in the pathogenesis of hepatocellular carcinoma complicating chronic hepatitis C: an immunohistochemical and PCR study of human liver biopsies. BMC Res. Notes 2012, 5:390.
126. Yang T., et al. Bone morphogenetic protein 7 suppresses the progression of hepatic fibrosis and regulates the expression of Gremlin and transforming growth factor β1. Mol. Med. Rep. 2012, 6:246-252.
127. 4-induced hepatic fibrosis in mice. Mol. Ther. 2012, 20:2043-2051.
128. Yoshida K., et al. TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review). Int. J. Oncol. 2014, 45:1363-1371.
129. Passa O., et al. Compartmentalization of bone morphogenetic proteins and their antagonists in lymphoid progenitors and supporting microenvironments and functional implications. Immunology 2011, 134:349-359.
130. Tsalavos S., et al. Involvement of twisted gastrulation in T cell-independent plasma cell production. J. Immunol. 2011, 186:6860-6870.
131. Myers M., et al. Loss of Gremlin delays primordial follicle assembly but does not affect female fertility in mice. Biol. Reprod. 2011, 85:1175-1182.
132. Ali I.H., Brazil D.P. Bone morphogenetic proteins and their antagonists: current and emerging clinical uses. Br. J. Pharmacol. 2014, 171:3620-3632.
133. Miyazono K., et al. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 2010, 147:35-51.
134. Gautschi O.P., et al. Bone morphogenetic proteins in clinical applications. ANZ J. Surg. 2007, 77:626-631.
135. Epstein N.E. Complications due to the use of BMP/INFUSE in spine surgery: the evidence continues to mount. Surg. Neurol. Int. 2013, 4:S343-S352.
136. Zeisberg E.M., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13:952-961.
137. Kang Y.H., et al. Bone morphogenetic protein-7 inhibits vascular calcification induced by high vitamin D in mice. Tohoku J. Exp. Med. 2010, 221:299-307.
138. Hao Z., et al. Intracolonically administered adeno-associated virus-bone morphogenetic protein-7 ameliorates dextran sulphate sodium-induced acute colitis in rats. J. Gene Med. 2012, 14:482-490.
139. Heinonen A.M., et al. Neuroprotection by rAAV-mediated gene transfer of bone morphogenic protein 7. BMC Neurosci. 2014, 15:38.
140. Tandon A., et al. BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PLoS ONE 2013, 8:e66434.
141. Vukicevic S., et al. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J. Clin. Invest. 1998, 102:202-214.
142. Zeisberg M., et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. 2003, 285:F1060-F1067.
143. Sugimoto H., et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007, 56:1825-1833.
144. Dudas P.L., et al. BMP-7 fails to attenuate TGF-β1-induced epithelial-to-mesenchymal transition in human proximal tubule epithelial cells. Nephrol. Dial. Transplant. 2009, 24:1406-1416.
145. Murray L.A., et al. BMP-7 does not protect against bleomycin-induced lung or skin fibrosis. PLoS One 2008, 3:e4039.
146. Sugimoto H., et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis. Nat. Med. 2012, 18:396-404.
147. Whitman M., et al. Regarding the mechanism of action of a proposed peptide agonist of the bone morphogenetic protein receptor activin-like kinase 3. Nat. Med. 2013, 19:809-810.
148. Vrijens K., et al. Identification of small molecule activators of BMP signaling. PLoS ONE 2013, 8:e59045.
149. Lepparanta O., et al. Bone morphogenetic protein-inducer tilorone identified by high-throughput screening is antifibrotic in vivo. Am. J. Respir. Cell Mol. Biol. 2013, 48:448-455.
150. Lin J., et al. Kielin/Chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 2005, 11:387-393.
151. Lin J., et al. The cysteine-rich domain protein KCP is a suppressor of transforming growth factor beta/activin signaling in renal epithelia. Mol. Cell. Biol. 2006, 26:4577-4585.
152. Soofi A., et al. Kielin/Chordin-like protein attenuates both acute and chronic renal injury. J. Am. Soc. Nephrol. 2013, 24:897-905.
153. 4 attenuate experimental renal fibrosis. FASEB J. 2011, 25:2967-2979.
154. 4, a potential anti-inflammatory drug targeting the skin. J. Dermatol. Sci. 2011, 62:67-69.
155. Meng F., et al. Attenuation of LPS-induced lung vascular stiffening by lipoxin reduces lung inflammation. Am. J. Respir. Cell Mol. Biol. 2014, Published online July 3, 2014. http://dx.doi.org/10.1165/rcmb.2013-0468OC.
156. Brennan E.P., et al. Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFβR1. J. Am. Soc. Nephrol. 2013, 24:627-637.
157. Tang O., et al. MiRNA-200b represses transforming growth factor-β1-induced EMT and fibronectin expression in kidney proximal tubular cells. Am. J. Physiol. Renal Physiol. 2013, 304:F1266-F1273.
158. Yu P.B., et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat. Chem. Biol. 2008, 4:33-41.
159. Boergermann J.H., et al. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells. Int. J. Biochem. Cell Biol. 2010, 42:1802-1807.
160. Hao J., et al. Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. PLoS ONE 2008, 3:e2904.
161. Hao J., et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem. Biol. 2010, 5:245-253.
162. Ao A., et al. DMH1, a novel BMP small molecule inhibitor, increases cardiomyocyte progenitors and promotes cardiac differentiation in mouse embryonic stem cells. PLoS One 2012, 7:e41627.
163. Sanvitale C.E., et al. A new class of small molecule inhibitor of BMP signaling. PLoS ONE 2013, 8:e62721.
164. Myllarniemi M., et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008, 177:321-329.
165. Farkas L., et al. Transient overexpression of Gremlin results in epithelial activation and reversible fibrosis in rat lungs. Am. J. Respir. Cell Mol. Biol. 2011, 44:870-878.
166. Liu D., Morrell N.W. Genetics and the molecular pathogenesis of pulmonary arterial hypertension. Curr. Hypertens. Rep. 2013, 15:632-637.
167. Cahill E., et al. Gremlin plays a key role in the pathogenesis of pulmonary hypertension. Circulation 2012, 125:920-930.
168. Costello C.M., et al. Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist Gremlin in pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 295:L272-L284.
169. Ciuclan L., et al. Treatment with anti-Gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice. Am. J. Pathol. 2013, 183:1461-1473.
170. Nolan K., Thompson T.B. The DAN family: modulators of TGF-β signaling and beyond. Protein Sci. 2014, 23:999-1012.
171. Hwang S., et al. miR-140-5p suppresses BMP2-mediated osteogenesis in undifferentiated human mesenchymal stem cells. FEBS Lett. 2014, 588:2957-2963.
172. Kureel J., et al. miR-542-3p suppresses osteoblast cell proliferation and differentiation, targets BMP-7 signaling and inhibits bone formation. Cell Death Dis. 2014, 5:e1050.
173. Itoh T., et al. MicroRNA-208 modulates BMP-2-stimulated mouse preosteoblast differentiation by directly targeting V-ets erythroblastosis virus E26 oncogene homolog 1. J. Biol. Chem. 2010, 285:27745-27752.
174. Wu T., et al. miR-30 family members negatively regulate osteoblast differentiation. J. Biol. Chem. 2012, 287:7503-7511.
175. Wu T., et al. miR-155 modulates TNF-α-inhibited osteogenic differentiation by targeting SOCS1 expression. Bone 2012, 51:498-505.
176. Xiao F., et al. MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling. Oncogene 2014, Published online June 2, 2014. http://dx.doi.org/10.1038/onc.2014.
177. Hamada S., et al. miR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX. Cell. Signal. 2014, 26:179-185.
178. Hu F., et al. BMP-6 inhibits cell proliferation by targeting microRNA-192 in breast cancer. Biochim. Biophys. Acta 2013, 1832:2379-2390.
179. Nishida N., et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin. Cancer Res. 2012, 18:3054-3070.
180. Dey B.K., et al. The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. Genes Dev. 2014, 28:491-501.
181. Dey B.K., et al. miR-26a is required for skeletal muscle differentiation and regeneration in mice. Genes Dev. 2012, 26:2180-2191.
182. Liu H., et al. miR-30b is involved in methylglyoxal-induced epithelial-mesenchymal transition of peritoneal mesothelial cells in rats. Cell. Mol. Biol. Lett. 2014, 19:315-329.
183. Kim E.J., et al. Failure of tooth formation mediated by miR-135a overexpression via BMP signaling. J. Dent. Res. 2014, 93:571-575.
184. Zhang X.Q., et al. Regulation of pulmonary surfactant synthesis in fetal rat type II alveolar epithelial cells by microRNA-26a. Pediatr. Pulmonol. 2014, 49:863-872.
185. Icli B., et al. MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ. Res. 2013, 113:1231-1241.
186. Parikh V.N., et al. MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach. Circulation 2012, 125:1520-1532.
187. Lipchina I., et al. Genome-wide identification of microRNA targets in human ES cells reveals a role for miR-302 in modulating BMP response. Genes Dev. 2011, 25:2173-2186.
188. Chan M.C., et al. Molecular basis for antagonism between PDGF and the TGFβ family of signalling pathways by control of miR-24 expression. EMBO J. 2010, 29:559-573.
189. Sun J., et al. BMP4 activation and secretion are negatively regulated by an intracellular Gremlin-BMP4 interaction. J. Biol. Chem. 2006, 281:29349-29356.
190. Tsugawa D., et al. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J. Pharmacol. Exp. Ther. 2014, 351:549-558.
191. Andriopoulos B., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet. 2009, 41:482-487.
192. Grafe I., et al. Excessive transforming growth factor-beta signaling is a common mechanism in osteogenesis imperfecta. Nat. Med. 2014, 20:670-675.
193. Yu P.B., et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat. Med. 2008, 14:1363-1369.
194. Windisch P., et al. A Phase IIa randomized controlled pilot study evaluating the safety and clinical outcomes following the use of rhGDF-5/β-TCP in regenerative periodontal therapy. Clin. Oral Invest. 2012, 16:1181-1189.
195. Langdon J.M., et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am. J. Hematol. 2015, 90:8-14.